AtaiBeckley Inc. ATAI
Founded in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, AtaiBeckley is a clinical-stage biotechnology company on a mission to create breakthroughs for people with difficult-to-treat mental health conditions. Our work is grounded in rigorous science to deliver meaningful outcomes for the patients we serve.
Mental health disorders are highly prevalent and estimated to affect more than one billion people globally. The economic burden of these disorders is substantial and is growing rapidly. Between 2009 and 2019, spending on mental health care in the United States increased by more than 50%, reaching $225.0 billion, and a Lancet Commission report estimates that the global economic cost will reach $16.0 trillion by 2030. While current treatments, such as selective serotonin reuptake inhibitors ("SSRIs") and serotonin-norepinephrine reuptake inhibitors ("SNRIs") are well established and effective for certain patients, approximately 65% of patients do not achieve remission of their symptoms after up to four antidepressant treatment trials, translating to a significant unmet medical need.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $4.1M | $308.0K | — |
| R&D | — | $900.0K | — |
| SG&A | $65.1M | $47.5M | — |
| Total operating expenses | $648.1M | $103.0M | — |
| Operating income | -$644.1M | -$102.7M | — |
| Interest expense | $1.2M | $3.1M | — |
| Pre-tax income | -$659.8M | -$148.4M | — |
| Income tax | $298.0K | $356.0K | — |
| Net income | -$660.0M | -$149.3M | — |
| EPS, basic | -2.91 | -0.93 | — |
| EPS, diluted | -2.91 | -0.93 | — |
| Shares, diluted (wtd. avg.) | $226.5M | $160.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $85.3M | $17.5M | $45.0M |
| Receivables | $667.0K | $354.0K | — |
| Total current assets | $275.7M | $80.1M | — |
| Property, plant and equipment | $2.2M | $2.5M | — |
| Goodwill | $331.0K | $331.0K | — |
| Other intangibles | $2.9M | $3.2M | — |
| Total assets | $292.7M | $159.4M | — |
| Accounts payable | $4.9M | $2.6M | — |
| Short-term debt | $135.4M | $6.4M | — |
| Total current liabilities | $23.5M | $25.0M | — |
| Long-term debt | $0 | $14.1M | — |
| Total liabilities | $70.7M | $42.8M | — |
| Retained earnings | -$1.36B | -$700.2M | — |
| Total equity | $221.9M | $116.3M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$102.7M | -$82.4M | — |
| Depreciation and amortisation | $1.0M | $473.0K | — |
| Stock-based compensation | $14.2M | $25.5M | — |
| Capital expenditure | $901.0K | $6.0K | — |
| Investing cash flow | -$109.1M | $59.2M | — |
| Financing cash flow | $269.5M | $5.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-096926.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |